Related Experiment Video
Updated: Feb 6, 2026
07:10
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
Published on: June 18, 2020
22.8K
Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver
Bernhard Scheiner1,2, Lisa Steininger1,2, Georg Semmler1,2
1Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Summary
Controlled attenuation parameter (CAP) does not predict hepatic decompensation in patients with advanced chronic liver disease. Serum albumin and MELD-Na scores are better indicators of prognosis in these patients.
Area of Science:
- Hepatology
- Liver Disease Prognostics
- Non-invasive Liver Assessment
Background:
- Transient elastography (TE)-based controlled attenuation parameter (CAP) is used to assess hepatic steatosis.
- The predictive value of CAP for hepatic decompensation in advanced liver disease is under investigation.
Purpose of the Study:
- To evaluate the prognostic value of CAP in patients with compensated advanced chronic liver disease (cACLD).
- To assess the prognostic value of CAP in patients with decompensated cirrhosis (DC).
Main Methods:
- Retrospective analysis of 430 patients undergoing TE and CAP measurements.
- Definition of hepatic decompensation varied for cACLD and DC groups.
- Follow-up duration was 22 months for cACLD and 12 months for DC patients.
Main Results:
- CAP was not predictive of first hepatic decompensation in cACLD or further decompensation in DC patients.
- Patients with CAP ≥248 dB/m showed similar decompensation rates compared to those without.
- Serum albumin and MELD-Na were independently associated with hepatic decompensation in both patient groups.
Conclusions:
- Controlled attenuation parameter (CAP) does not predict hepatic decompensation in cACLD or DC.
- Serum albumin levels and MELD-Na score are significant prognostic markers for hepatic decompensation.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
206
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
206
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
01:26Diseases of the Liver and Gallbladder
2.0K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.0K
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
247
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
247
02:42Transcription Attenuation in Prokaryotes
18.5K
Transcriptional attenuation occurs when RNA transcription is prematurely terminated due to the formation of a terminator mRNA hairpin structure. Bacteria use these hairpins to regulate the transcription process and control the synthesis of several amino acids including histidine, lysine, threonine, and phenylalanine. Transcription attenuation takes place in the non-coding regions of mRNA.
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
18.5K
01:25Chronic Kidney Disease I: Introduction
740
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
740